TSE:4502Pharmaceuticals
Takeda Pharmaceutical (TSE:4502) Margin Compression To 2.5% Reinforces Bearish Profitability Narratives
Takeda Pharmaceutical (TSE:4502) has posted Q3 2026 revenue of ¥1.19t and basic EPS of ¥65.65, with trailing twelve month EPS at ¥71.70 and net income of ¥112.93b giving investors a fresh read on profitability after a period that included a large one off loss of ¥143.7b. The company has seen quarterly revenue move between ¥1.06t in Q4 2025 and ¥1.19t in Q3 2026. Basic EPS has swung from a loss of ¥65.22 per share in Q4 2025 to ¥79.40 in Q1, a small loss of ¥7.48 in Q2 and the latest ¥65.65 in...